Mannkind Corp
0 products tracked · names used in filings: Mannkind Corp
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Furoscix ReadyFlow Autoinjector: PDUFA target action date
Mannkind Corp (MNKD); furosemide injection; status: set; "Q1 2025 Built out launch infrastructure and aligned field-based teams for upcoming launches Settlement of senior convertible notes of $36.3M Program updates: Afrezza ® pediatric indication PDUFA date May 29, 2026 Furoscix ReadyFlow ™ Autoinjector PDUFA date July 26, 2026 Nintedanib DPI (MNKD-201) for…"; filed 2026-05-06 · source
Afrezza: PDUFA target action date (type 1 or type 2 diabetes in children and adolescents aged 4-17)
Mannkind Corp (MNKD); sBLA; status: set; "In October 2025, the FDA accepted for review a supplemental BLA for Afrezza in children and adolescents between the ages of 4-17 who are living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026."; filed 2026-05-28 · source
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.